Custom Antibody Production, CAR-T Services, mRNA-LNP

Fueling A New Era In Medicine

Since 2001, ProMab has built in-house expertise in the latest technologies to help our partners push the frontiers of medicine.

Today, we are the only provider that can offer CAR-T/NK development, mRNA-LNP development, and antibody engineering-highly promising technologies on their own and even more powerful when combined.

Turn tumors into cancer vaccines, manufacture antibodies in the body, revolutionize cancer care... imagine the possibilities and we'll help you bring them to life.


monoclonal antibodies generated


filed patents


CAR-T projects finished


Phase 2 clinical trials started

Featured Publications

mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth Cancers (Basel). 2023 May; 15(10): 2860.
Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth Cancers (Basel). 2022 May 20;14(10):2518.
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma Cancers (Basel). 2021 Mar; 13(5): 981.